Altrika Limited (“Altrika”) is delighted to announce a new development project being undertaken for the Industrial Technology Research Institute (“ITRI”) in Taiwan. The programme will make use of Altrika’s high throughput materials discovery capability for bio-functional polymers to support a key tissue regeneration research project run by ITRI’s Biomedical Engineering Research Lab (BEL).
Altrika improves human health through the discovery of novel materials which can enable the next generation of medical devices. It supplies and develops new products using materials which actively contribute to the prevention of disease and recovery from illness. Altrika has already commercialised two products, CryoSkin and MySkin, which are used for the treatment of burns.
ITRI is well known for its world-leading technical innovation. It pioneered commercial success in the semi-conductor industry in Taiwan, having developed the technology behind both UMC and TSMC, the world’s largest semiconductor fabrication company.
“This programme with ITRI is another vote of confidence from a world-leading organisation in Altrika and our materials discovery capabilities,” said Graeme Purdy, CEO of Altrika. “ITRI’s track record in commercializing novel technologies makes them an ideal partner for us and we are very excited by the potential of this novel form of treatment.”
“Altrika provides the answer to one of our key technical challenges in this development,” said Dr. Chungcheng Liu, General Director of ITRI BEL. “Their ability to screen such large libraries of materials so quickly will provide us with a highly functional and cost effective treatment. We are very pleased to be have secured them as our partner.”
– Ends –
For further details, please contact:
Pelham Bell Pottinger (Financial Public Relations to Ilika)
Tel. +44 23 8011 1400
Tel. +44 114 222 0985
Mob. +44 7818 034572
Tel. +44 20 7861 3232
Chief Executive Officer
Richard Snell, Business Development Director
About Altrika Ltd.: Altrika Ltd. is a wholly owned subsidiary of Ilika plc, a global leader in high throughput materials discovery. The Company was founded in December 2008 to focus on the development and exploitation of novel materials in the biomedical sector. Altrika works with leading medtech companies to identify novel materials for specific applications, as well as developing solutions in-house for the next generation of medical products. Altrika runs a GMP manufacturing facility in Sheffield, UK, licensed by both the UK Human Tissue Authority (HTA) and Medicines and Healthcare products Regulatory Agency (MHRA) to supply its Cryoskin® and Myskin® services on a named patient basis exclusively at the request of, and under the responsibility of, the treating clinician
The Industrial Technology Research Institute (ITRI) is a not-for-profit R&D organization engaging in applied research and technical services. Founded in 1973, ITRI has played a vital role in transforming Taiwan’s economy from a labor-intensive industry to a high-tech industry. Numerous well-known high-tech companies in Taiwan, such as leaders in the semiconductor industry TSMC and UMC, can trace their origins to ITRI.
ITRI is a multidisciplinary research center, with six core laboratories, five focus centers, five linkage centers, several leading labs and various business development units. The six fields ITRI focuses on include Information and Communication; Electronics and Optoelectronics; Material, Chemical and Nanotechnologies; Biomedical Technologies; Advanced Manufacturing and Systems; and Energy and Environment. ITRI has aggressively researched and developed countless next-generation technologies, including WIMAX wireless broadband, solar cells, RFID, light electric vehicles, flexible displays, 3-D ICs and telecare technologies. In addition, ITRI’s Flexible Electronics Pilot Lab and Nanotechnology Lab provide international-level research platforms where R&D can be conducted jointly with partners. ITRI has also seen significant growth in intellectual property business and new ventures in recent years and is devoted to creating a model that would make Taiwan manufacturing even more competitive in the international arena.
Fostering Entrepreneurship and CEO Leadership
ITRI employs 5,800 personnel, including 1,112 who hold Ph.D.s and 3,206 with master’s degrees, resulting in an average of five patents produced every day. By disseminating both technology and talent, ITRI has led the technology industry into the 21st century and has cultivated 70 CEOs in the local high-tech industry. In addition to its headquarters in Taiwan, ITRI has branch offices in the California Silicon Valley, Tokyo, Berlin and Moscow.